Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31525039 | 0.87 | GABRA5 (0.43) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Trifluoroacetic Acid SCHEMBL28212086 | 0.87 | GABRA5 (0.43) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Carbamic Acid SCHEMBL7512746 | 0.81 | GABRA5 (0.50) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Trifluoroacetic Acid SCHEMBL30804039 | 0.80 | GABRA5 (0.38) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Trifluoroacetamide SCHEMBL28698449 | 0.76 | KDM4E (0.39) | TSHRNOS2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL62516 | 0.75 | — | — | |
| Trifluoroacetic Acid SCHEMBL1695704 | 0.75 | SLC6A1 (0.42) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Trifluoroacetic Acid SCHEMBL28210823 | 0.75 | SLC6A1 (0.42) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Trifluoroacetamide SCHEMBL17924048 | 0.75 | ALDH1A1 (0.45) | EPHX1KDM4EMAPTKMT2AATM | |
| Trifluoroacetamide SCHEMBL27862700 | 0.75 | ALDH1A1 (0.38) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3858993-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | Sarepta Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858847-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | Sarepta Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10905709-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-2785729-B1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | SAREPTA THERAPEUTICS INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10577605-B2 | Induced exon inclusion in spinal muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190177723-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-06-13 | — | — | US | disclosed |
| US-20190100755-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-04-04 | — | — | US | disclosed |
| EP-3341480-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | Sarepta Therapeutics, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9944926-B2 | Induced exon inclusion in spinal muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| WO-2017062835-A2 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017040271-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20140329772-A1 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140303238-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | SAREPTA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2785729-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | Sarepta Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2785840-A1 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY | Sarepta Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013082551-A1 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013082548-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | SAREPTA THERAPEUTICS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | GABRA5 1696/4885GABRB2 1588/4885GABRA1 2440/4885 |
| US-20190100755-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | GABRA5 1696/4885GABRB2 1588/4885GABRA1 2440/4885 |
| US-20190177723-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | UTRN, SMN1; SMN2, MTPN | GABRA5 1904/4885GABRB2 836/4885GABRA1 1797/4885 |
| US-10905709-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SMN1; SMN2, UPF1, RBM17 | GABRA5 1980/4885GABRB2 865/4885GABRA1 2183/4885 |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | HTT, UPF1, TARDBP | GABRA5 1696/4885GABRB2 1588/4885GABRA1 2440/4885 |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | GABRA5 1980/4885GABRB2 865/4885GABRA1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.